NASDAQ$PRME

Prime Medicine Inc · Q4 2019 earnings

Q4 2019 earnings · · Investor relations

Headline financials

EPS (adj)

-$0.04

No prior period
Net Income

-$2.53M

No prior period
Operating Income

-$2.17M

No prior period
Gross Profit

$0.00

No prior period
R&D Expense

$920K

No prior period

Revenue & EPS history

Prime Medicine · Revenue · Quarterly

$1.65M

Q4 2025-44.7%vs Q4 2024
Beat estimate in 0 of 8 quarters(0%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 14 quarterly earnings reports

Historical avg

-1.7%

Avg return

Earnings day

-7.2%

Avg return

5 days after

-10.8%

Avg return

30 days after

29%

5 / 17 earnings

Positive

+26.6%

Q1 2025

Best reaction

-9.8%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025-8.2%-13.9%-28.8%
Q3 2025-9.1%-15.1%-10.5%
Q1 2025+26.6%-7.5%+15.9%
Q4 2024+4.1%-4.5%-17.8%
Q3 2024-9.8%-23.8%-31.4%
Q2 2024-4.5%-2.5%-19.3%
Q1 2024+12.2%+18.2%+14.9%
Q4 2023+1.6%-2.4%-18.9%
Q3 2023+17.0%+13.1%+21.6%
Q2 2023-7.5%-14.9%-13.3%
Q1 2022-9.4%-10.5%+3.2%
Q1 2023-9.4%-10.5%+3.2%
Q4 2020-9.7%-11.7%-21.9%
Q4 2022-9.7%-11.7%-21.9%
Q3 2022-4.4%-8.1%-19.4%
Q3 2021-4.4%-8.1%-19.4%
Q4 2021-4.4%-8.1%-19.4%
Q2 2021
Q1 2021
Q4 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro